Novo Nordisk A/S engages in the research, development, manufacture, and marketing of pharmaceutical products.The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in areas of haemophilia, growth disorders, and hormone replacement therapy. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
